enGene Appoints Heffernan Chairman Ahead of Planned 2027 FDA Approval
enGene Therapeutics named Michael Heffernan chairman, replacing Dr. Richard Glickman, to better support commercial goals. The company outlined regulatory timelines including a planned BLA submission and potential 2027 approval for its NMIBC treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day